Regeneron Pharmaceuticals REGN

Regeneron Pharmaceuticals Inc. is an American biotechnology company headquartered in Westchester County, New York. The firm is involved in the discovery, development and commercialisation of various medical solutions for patients suffering with eye diseases, allergic and inflammatory diseases, various cancers, cardiovascular and metabolic diseases, chronic pain, hematologic diseases, infectious diseases and rare diseases. The firm was founded in 1988.

Current commercialised products available from the firm include Dupixent, for the treatment of moderate-to-severe atopic dermatitis (eczema), Evkeeza, a treatment for the high cholesterol condition homozygous familial hypercholesterolemia (HoFH), and Eylea, for the treatment of patients with wet Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

The company employs around 10,000 people worldwide, around 1,100 of whom hold an MD, PhD or PharmD degree, and who were published in more than 175 peer-reviewed publications in 2020 alone. The company has around 30 product candidates in development across numerous therapeutic areas. The firm is listed on the NASDAQ where it trades under the stock ticker REGN.

If you are interested in Regeneron Pharmaceuticals stock, you can track the share price by adding REGN stock to your digital watchlist.